FDA Approves Azacitidine Tablets for Acute Myeloid Leukaemia
Efficacy was investigated in the QUAZAR study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with Advanced Cancer
A qualitative next generation sequencing based in vitro diagnostic test analyzes more than 300 genes and genomic signatures
Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre in Vienna
Low SARS-CoV-2 seroprevalence in both, oncology healthcare workers and cancer patients require continuation of strict safety measures
No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib vs Chemotherapy
Final overall survival data from the AURA3 study possibly impacted by a high percentage of treatment crossover
Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without Detrimental Effects on Patient Health Status
Patient-centred outcomes in the ARIEL3 study
Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly Patients With STS
Findings from the EPAZ study
Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer
Results from the LIBRETTO-001 study
Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC
Restults from the LIBRETTO-001 study in RET fusion-positive non-small cell lung cancer
Male Patients with Cancer at Higher Risk of Severe Disease Course and Mortality Attributable to COVID-19
Findings from a systematic review and meta-analysis
A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL
Findings from the CheckMate 205 study
FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma
The efficacy was evaluated in CANDOR and EQUULEUS trials
Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer
Final overall survival results from the EMBRACA trial